Top Page
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
(2252)
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 257.25M | 104.59M | 21.60M | 2.15M | 0.00 |
| Gross Profit | 86.22M | 14.69M | 6.56M | 919.00K | 0.00 |
| EBITDA | -413.34M | -893.36M | -1.01B | -543.84M | -160.93M |
| Net Income | -642.41M | -1.01B | -1.17B | -542.69M | -261.25M |
Balance Sheet | |||||
| Total Assets | 1.28B | 1.43B | 1.93B | 2.79B | 1.70B |
| Cash, Cash Equivalents and Short-Term Investments | 612.23M | 507.71M | 747.96M | 1.94B | 1.50B |
| Total Debt | 691.33M | 560.42M | 219.95M | 204.68M | 18.88M |
| Total Liabilities | 1.02B | 926.15M | 522.25M | 401.73M | 262.90M |
| Stockholders Equity | 278.20M | 519.48M | 1.42B | 2.39B | 1.44B |
Cash Flow | |||||
| Free Cash Flow | -340.21M | -634.30M | -1.09B | -674.47M | -118.05M |
| Operating Cash Flow | -298.12M | -567.84M | -898.48M | -540.49M | -103.04M |
| Investing Cash Flow | -47.60M | -58.38M | -267.82M | -396.57M | -15.01M |
| Financing Cash Flow | 449.96M | 385.68M | -27.95M | 1.39B | 1.56B |
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$7.16B | 25.72 | 15.22% | 1.80% | 12.48% | 71.75% | |
65 Neutral | HK$7.60B | 32.29 | 6.49% | ― | 0.87% | -18.05% | |
62 Neutral | HK$6.22B | 20.85 | 10.92% | 1.30% | 20.19% | 45.54% | |
59 Neutral | HK$15.54B | 5.54 | -7.44% | 4.07% | 11.55% | -28.15% | |
51 Neutral | $15.91B | ― | -31.45% | ― | 8.11% | 55.55% | |
47 Neutral | HK$2.29B | ― | -2.19% | ― | 5.32% | 89.43% | |
46 Neutral | HK$16.85B | ― | -160.49% | ― | 141.72% | 38.39% |
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events
Shanghai MicroPort MedBot (Group) Co., Ltd. held its 2024 Annual General Meeting, where all proposed resolutions were approved, including the appointment of a new executive director and auditors. The company also established a Commercialisation Committee, indicating a strategic focus on expanding its market reach and operational capabilities.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
Shanghai MicroPort MedBot (Group) Co., Ltd. has announced the composition of its board of directors and their roles within the company. The announcement outlines the members of the board, including executive, non-executive, and independent non-executive directors, and details their participation in various board committees. This update is significant for stakeholders as it provides insights into the company’s governance structure and strategic direction.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
Shanghai MicroPort MedBot has announced a change in the use of proceeds from its recent placing of 34.7 million H shares, initially intended for business development and working capital. The company has decided to allocate the unutilized net proceeds of approximately HK$266.31 million towards repaying bank loans. This strategic reallocation aims to enhance financial flexibility, reduce interest expenses, and optimize the company’s financial structure, ultimately benefiting the company’s financial health and its shareholders.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
Shanghai MicroPort MedBot has announced that its cumulative order volume for core products has surpassed 130 units, with the Toumai Laparoscopic Surgical Robot receiving over 70 commercial orders globally. The company has achieved significant milestones in remote surgery, including the first robot-assisted remote surgeries in Europe, showcasing its advanced technology systems. These developments highlight the company’s growing recognition and potential impact in the global surgical robotics market.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
Shanghai MicroPort MedBot (Group) Co., Ltd. announced the convening of its Annual General Meeting on June 25, 2025, to discuss and approve several key resolutions. These include the approval of the 2024 Annual Report, the appointment of new directors and auditors, and the granting of mandates to issue additional shares and buy back shares. These resolutions are expected to impact the company’s capital structure and operational strategies, potentially influencing its market positioning and shareholder value.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
Shanghai MicroPort MedBot (Group) Co., Ltd. announced the successful completion of placing 25,136,500 new H shares at HK$15.5 per share, raising approximately HK$382.33 million in net proceeds. The funds will be used primarily for the development and commercialization of the company’s core business products, both locally and overseas, as well as for research and development to enhance product performance. Additionally, 30% of the proceeds will be allocated to replenishing working capital and general corporate purposes, with an expected utilization by the end of 2027. The placing did not result in any new substantial shareholders.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
Shanghai MicroPort MedBot (Group) Co., Ltd. announced a strategic move involving the placement of 25,136,500 new H shares, representing approximately 2.50% of its issued share capital, to be procured by placing agents. This initiative aims to strengthen the company’s capital base and enhance its market presence. Concurrently, the controlling shareholder plans to sell 30,163,500 shares, accounting for about 3.00% of the company’s issued share capital, through a block trade agreement. These transactions are independent of each other and may not proceed if certain conditions are not met, highlighting the company’s efforts to optimize its shareholder structure and attract new investors.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
Shanghai MicroPort MedBot (Group) Co., Ltd. has announced plans for a proposed placing of new H shares and a proposed sale of existing H shares by its controlling shareholder. The proposed placing involves issuing new H shares to certain investors under a general mandate, with terms to be determined through a book-building exercise. The proposed sale involves the controlling shareholder disposing of certain existing H shares. These two transactions are independent of each other and may not occur simultaneously. No binding agreements have been made yet, and the company advises investors and shareholders to exercise caution.
The most recent analyst rating on (HK:2252) stock is a Buy with a HK$9.50 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
Shanghai MicroPort MedBot (Group) Co., Ltd. announced the resignation of Mr. Chen Xinxing as a non-executive director and audit committee member, effective April 30, 2025, as he intends to focus on other work commitments. The board expressed gratitude for his contributions and confirmed no disagreements with the board. Following his departure, the audit committee will be restructured to include Mr. Chung Wai Man, Dr. Li Minghua, and Mr. Yao Haisong, with Mr. Chung continuing as chairperson.
Shanghai MicroPort MedBot (Group) Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is significant as it outlines the leadership structure and strategic direction of the company, which could influence its operations and market positioning within the medical technology industry.
Shanghai MicroPort MedBot has achieved a significant milestone with the approval of its Toumai Remote laparoscopic surgical robot by the National Medical Products Administration of China. This approval marks the world’s first for full-department application in remote surgery, enhancing the company’s product portfolio and positioning it as a leader in the global remote surgery field. The Toumai Remote system, compatible with multiple communication networks, has been instrumental in performing nearly 400 remote surgeries across various countries, showcasing its innovative capabilities and establishing numerous national and world records.